Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7975715 | 0.87 | RAB9A (0.56) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL8886349 | 0.86 | MAPT (0.59) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL4892299 | 0.85 | LMNA (0.51) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL8886856 | 0.82 | KMT2A (0.55) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL4905065 | 0.80 | MEN1 (0.55) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL4932353 | 0.80 | MEN1 (0.60) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL471095 | 0.79 | MAPT (0.63) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL7402604 | 0.78 | MAPT (0.66) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL14463550 | 0.78 | KMT2A (0.58) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL4892335 | 0.77 | KMT2A (0.46) | NPC1RAB9AKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132551-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | PFIZER INC | 2008-06-05 | — | — | US | disclosed |
| EP-1611128-A2 | POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR | Pharmacia & Upjohn Company LLC (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004085433-A2 | POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132551-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | CHRNA1, CHRNA7, CHRNA5 | NPC1 2122/4885RAB9A 888/4885KMT2A 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.